7/23/2024 - Hi-Risk/Recurrent/Advanced PCa Men & Caregiver

UPCOMING AnCan CLINICAL TRIALS WEBINAR
Clinical Trials 101: Common Myths and Facts
Date: Wednesday July 31, 8.00 pm Eastern

AnCan is grateful to the following sponsors for making this recording possible: Bayer, Foundation Medicine, Janssen, Myriad Genetics, Novartis, Telix & Blue Earth Diagnostics.

AnCan respectfully notes that it does not accept sponsored promotion. Any drugs, protocols or devices recommended in our discussions are based solely on anecdotal peer experience or clinical evidence.

AnCan cannot and does not provide medical advice. We encourage you to discuss anything you hear in our sessions with your own medical team.

Editors Pick: The passing of Jim Barnes; ADT know-how from Richard Wassersug (bn)

Topics Discussed

Passing of Jim Barnes, age 65 -- his mutations (P53 and PTEN) may have made actinium/lutetium treatments ineffective; a delicate spot radiation gets moved earlier; after five years of remission, PSA drifts just high enough to be worrisome; blood clots in lungs after his final Provenge infusion  -- "I actually could feel bumps";  scary bright spot in his PSMA PET appears to be a prostate cyst; OK to start Casodex and Lupron at the same time?; a mini-webinar from Dr. Wassersug on ADT preparedness; Dr. W says metformin does not appear to forestall ADT-induced diabetes; and he updates us on his still-unproven but intriguing estradiol treatments -- note, please, that they're not a way to avoid ADT symptoms!; new team is eyeing PSA before starting radiation; testosterone still trailing after 2-year treatment holiday; at Carbone, we like Dr. Lang -- also take advantage of Carbone's palliative care, and be honest with them.

Chat Log

Richard Fiske · 6:30 PM
Sorry; have to leave.

AnCan - rick · 7:07 PM

AnCan - rick · 7:11 PM

AnCan - rick · 7:38 PM

[salsamink]

Has anyone had issues with low platelets count under 50, 000 caused by pluvicto, that now won’t stabilize. Went up with platelet transfusion, but then continues to decrease again.